Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxygen Transport Impairment in the Failing Heart: A Histology-Image-Based Computational Analysis.

Annals of biomedical engineering·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study.

Journal of the American College of Cardiology·2026
Same author

Distinct blood transcriptomic profiling underlying asthma establishment and exacerbation.

The journal of allergy and clinical immunology. Global·2026
Same author

The environmental exposome in heart failure risk and progression.

Nature reviews. Cardiology·2026
Same author

Development of a comprehensive cardiovascular disease genetic risk assessment test.

Genetics in medicine open·2026

Related Experiment Video

Updated: May 27, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Pharmacogenetics in chronic heart failure: new developments and current challenges.

Jasmine A Talameh1, David E Lanfear

  • 1UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Current Heart Failure Reports
|December 3, 2011
PubMed
Summary

Patient responses to heart failure (HF) drugs vary greatly. Genetic factors may explain some of this variability, guiding personalized HF pharmacotherapy. This review explores HF pharmacogenetics.

Related Experiment Videos

Last Updated: May 27, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

  • Pharmacogenetics
  • Cardiology
  • Genomics

Background:

  • Individual responses to heart failure (HF) pharmacotherapies show significant variability.
  • Clinical characteristics alone do not fully explain treatment response disparities.
  • Genetic variations are increasingly recognized as a potential contributing factor to HF drug efficacy and toxicity.

Purpose of the Study:

  • To review the existing pharmacogenetic literature for key HF drug classes.
  • To evaluate recent advancements in HF pharmacogenetics.
  • To discuss challenges and future clinical applications of HF pharmacogenetic data.

Main Methods:

  • Literature review of pharmacogenetic studies.
  • Synthesis of findings for β-blockers, ACE inhibitors, digoxin, and loop diuretics.
  • Analysis of recent research in the context of established knowledge.

Main Results:

  • Summary of genetic associations with HF pharmacotherapy response.
  • Identification of key genes and variants influencing drug metabolism and action.
  • Evaluation of the consistency and novelty of recent findings.

Conclusions:

  • Pharmacogenetics offers potential for personalized HF treatment strategies.
  • Further research is needed to overcome challenges in data interpretation and clinical implementation.
  • Integrating genetic information could optimize HF pharmacotherapy for improved patient outcomes.